From: kristoff@GENBANK.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 30, pt. 1, 21 August 1992
Date: 21 Aug 92 19:15:27 GMT
Distribution: bionet


$$XID NIHGUIDE 19920821 V21N30 P1O1 ************************************
X-comment: RFAs described: CA/NR-92-26, AI-92-11, CA-92-25, PA-92-101

NIH GUIDE - Vol. 21, No. 30 - August 21, 1992

$$INDEX BEGIN *******************************************************

                               NOTICES

$$INDEX N1 **********************************************************

ENVIRONMENTAL HEALTH SCIENCES CORE CENTER GRANTS PROGRAM
National Institute of Environmental Health Sciences
INDEX:  ENVIRONMENTAL HEALTH SCIENCES

$$INDEX N2 **********************************************************

RECEIPT DATES FOR NIEHS PROGRAM PROJECT (P01) APPLICATIONS
National Institute of Environmental Health Sciences
INDEX:  ENVIRONMENTAL HEALTH SCIENCES

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$INDEX R1 12/08/92 *************************************************

INTERVENTIONS TO ENHANCE ADJUSTMENT TO CANCER RISK OR DIAGNOSIS (RFA
CA/NR-92-26)
National Cancer Institute
National Center for Nursing Research
INDEX:  CANCER; NURSING RESEARCH

$$INDEX R2 11/20/92 *************************************************

THE EFFECTS OF SILICONE ON THE IMMUNE RESPONSE (RFA AI-92-11)
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES; ARTHRITIS, MUSCULOSKELETAL, SKIN
DISEASES

$$INDEX R3 12/22/92 *************************************************

INTERACTIVE R01S FOR CLINICAL STUDIES OF SYSTEMIC THERAPIES (RFA CA-92-
25)
National Cancer Institute
INDEX:  CANCER

                    ONGOING PROGRAM ANNOUNCEMENTS

$$INDEX P1 **********************************************************

RESEARCH ON ECONOMIC AND SOCIOECONOMIC ASPECTS OF ALCOHOL ABUSE (PA-92-
101)
National Institute on Alcohol Abuse and Alcoholism
INDEX:  ALCOHOL ABUSE, ALCOHOLISM

$$INDEX P2 **********************************************************

RESEARCH ON SURVEILLANCE AND RELATED STUDIES OF SPORTS INJURY IN YOUTH
(PA-92-102)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
INDEX:  ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES

                               ERRATA

$$INDEX E1 **********************************************************

RESEARCH SUPPLEMENTS TO PROMOTE REENTRY INTO BIOMEDICAL AND BEHAVIORAL
RESEARCH CAREERS
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH

This publication is also available electronically to institutions via
BITNET or INTERNET.  Alternative access is through the NIH Grant Line
using a personal computer.  Contact Dr. John James at 301/496-7554 for
details, or send an E-mail message to ZNS@NIHCU.

$$INDEX END *********************************************************

                      NOTICES

$$N1 BEGIN **********************************************************

ENVIRONMENTAL HEALTH SCIENCES CORE CENTER GRANTS PROGRAM

NIH GUIDE, Volume 21, Number 30, August 21, 1992

P.T. 34, 04; K.W. 0725005, 0710030, 0730070

National Institute of Environmental Health Sciences

This NOTICE is of a change of receipt date for this program to February
1 of each year.

The National Institute of Environmental Health Sciences (NIEHS) uses a
variety of award mechanisms to accomplish its mission of studying the
mechanisms and effects of environmental agents on human health.  Among
these are Environmental Health Sciences (EHS) Center Grants, a program
of core center support (P30).  The objective of this program is to
provide core support for an administrative structure, scientific
leadership, and shared core equipment to groups of productive
scientists with programs in environmental health.  The award allows
these scientists to:  (1) focus research efforts on issues of relevance
to the NIEHS, (2) work in an environment conducive to
inter-disciplinary approaches to such research; (3) serve as a resource
to the NIEHS in providing scientific expertise on critical public
health issues, and (4) engage in community outreach and education
programs dealing with regional environmental health issues.  A program
of smaller Marine and Freshwater Biomedical Sciences (MFBS) core center
grants is also supported focusing on the use of aquatic species as
biological models for environmental health research.  Direct research
support is NOT provided by the grant, except for limited funds for
pilot projects and exploratory research.

The NIEHS currently supports 13 EHS centers and 5 MFBS centers.  The
funding of additional centers is subject to budgetary and other
limitations.  Because of these limitations and the special nature of
the program, it is imperative that potential applicants contact NIEHS
staff to discuss the scope, content, size, and timing of any
applications for this program. In 1993, two extant EHS and one MFBS
center will be competing for funding.

INQUIRIES

Guidelines for this program, including fiscal limitations, review
criteria, and additional information are available from:

Dr. Christopher O. Schonwalder
Chief, Scientific Programs Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
104 Alexander Drive
Research Triangle Park, NC  27709
Telephone:  (919) 541-7634

$$N1 END ************************************************************

$$N2 BEGIN **********************************************************

RECEIPT DATES FOR NIEHS PROGRAM PROJECT (P01) APPLICATIONS

NIH GUIDE, Volume 21, Number 30, August 21, 1992

P.T. 34, 04; K.W. 0725005, 0710030, 0730070

National Institute of Environmental Health Sciences

The National Institute of Environmental Health Sciences (NIEHS)
announces a change in receipt dates for program project (P01)
applications.  Due to the newly announced receipt date for NIEHS core
center (P30) applications of February 1, (see Notice in this issue
titled:  Environmental Health Sciences Core Center Grants Program),
program project applications will not be received on this date.
Therefore, submissions will be accepted only for the annual June 1 and
October 1 receipt dates.

INQUIRIES

It is important that planned submissions be discussed with NIEHS
program staff as content, focus, and size of these applications are
critical factors in determining funding of these applications.

Inquiries about program project applications are to be directed to:

Dr. Thorsten Fjellstedt
Deputy Director, Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233
Research Triangle Park, NC  27709
Telephone:  (919) 541-0131

$$N2 END ************************************************************

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$R1 BEGIN CA/NR-92-26 FULL-TEXT ************************************

INTERVENTIONS TO ENHANCE ADJUSTMENT TO CANCER RISK OR DIAGNOSIS

NIH GUIDE, Volume 21, Number 30, August 21, 1992

P.T. 34; K.W. 0414014, 0715035, 0745020, 0411005

RFA AVAILABLE:  CA/NR-92-26

National Cancer Institute
National Center for Nursing Research

Letter of Intent Receipt Date:  September 18, 1992
Application Receipt Date:  December 8, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The National Cancer Institute (NCI) and the National Center for Nursing
Research (NCNR) invite investigator-initiated grant applications for
psychosocial research directed at improving the quality of life and
increasing compliance with treatment regimen of cancer patients or
adherence to early detection practices of persons at high risk of
cancer.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Interventions to Enhance Adjustment to Cancer Risk or Diagnosis, is
related to the priority area of cancer.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0 or Summary Report:  Stock No. 017-001-00473-1) through
the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325, telephone 202-783-3238.

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State and local
Governments, and eligible agencies of the Federal Government.
Applications from minority individuals and women are encouraged.

MECHANISM OF SUPPORT

This RFA will use the National Institutes of Health (NIH) individual
research grant (R01).  The applicant has sole responsibility for
planning, direction, and execution of the proposed project.  Total
project period for applications submitted in response to this RFA may
not exceed four years.

This RFA is a one-time solicitation.  Future unsolicited competitive
continuation applications will compete with all other
investigator-initiated research grant applications and be reviewed
according to the customary NIH peer review procedures.

FUNDS AVAILABLE

Total costs of $2,400,000 per year for four years will be committed to
specifically fund applications submitted in response to this RFA.  It
is anticipated that five to six awards will be made.  This funding
level is dependent upon the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NCI and the NCNR, the awards
pursuant to this RFA are also contingent upon the availability of funds
for this purpose.

RESEARCH OBJECTIVES

This RFA invites research to evaluate the impact of specific
psychosocial counseling interventions in persons notified of increased
cancer risk or newly diagnosed cancer patients with good prognosis.
Objectives are:  (1) to evaluate the efficacy of specific counseling
interventions in high-risk individuals and newly diagnosed cancer
patients, (2) to identify characteristics of successful interventions,
and (3) to assess the potential for community implementation.

Counseling is short-term, time-limited therapy addressing emotional and
adjustment issues of coping with risk or diagnosis of cancer, and
issues such as the need to comply with early detection guidelines or
initial treatment plans and medical follow-up.  Interventions may
include self-help or mutual support groups, behavioral interventions,
individual counseling programs, and pharmacologic adjunctive therapy.
Applications may incorporate existing but previously untested
interventions, adapt existing programs for specific patient groups, or
develop new interventions.  Outcome variables must include quality of
life and adherence/compliance with medical recommendations.

Interventions must target either (1) persons notified of increased risk
of cancers for which primary prevention methods are not proven, but for
which early detection is effective; or (2) newly diagnosed cancer
patients with reasonable chance of cure or prolonged survival with
state-of-the-art therapy.  Investigators must also evaluate the program
characteristics that contribute to efficacy and potential for transfer
of the intervention into the community setting.  A multi-disciplinary
approach is recommended.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without documentation
will not be accepted for review.

LETTER OF INTENT

Each prospective applicant is asked to submit, by September 18, 1992 a
letter of intent that includes a descriptive title of the proposed
research, the name, address, telephone/FAX numbers of the Principal
Investigator, the names of other key personnel and participating
institutions, and the number and title of the RFA in response to which
the application is being submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of a subsequent application, it contains
information that is helpful in planning for the review.  It allows NCI
and NCNR staff to estimate the potential review workload and to avoid
conflict of interest in the review.  The letter of intent is to be sent
to the Program Director named in INQUIRIES.

APPLICATION PROCEDURES

Applications must be received by close of business December 8, 1992.
Application forms (PHS 398 (rev. 9/91)) and information about
application procedures may be obtained from the NCI Program Director
named in INQUIRIES.

REVIEW CONSIDERATIONS

Applications that are competitive and responsive to the RFA will be
evaluated scientific and technical merit by an appropriate peer review
group according to specific review criteria.  A second level of review
will consider special needs and research priorities of NCI and NCNR.

INQUIRIES

Written and telephone requests for the RFA and the opportunity to
clarify any issues or questions from potential applicants are welcome.
Direct requests for the RFA and inquiries regarding programmatic issues
to:

Susan G. Nayfield, M.D., M.Sc.
National Cancer Institute
Executive Plaza North, Suite 300
Bethesda, MD  20892
Telephone:  (301) 496-8541

Directed inquiries regarding fiscal matters to:

Mrs. Eileen M. Natoli
National Cancer Institute
Executive Plaza South, Suite 242
Bethesda, MD  20892
Telephone:  (301) 496-7800

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.399, Cancer Control Research and 93.361, Nursing Research.
Awards are made under the authorization of the Public Health Service
Act, Title IV, Part A (Public Law 78-410, as amended by Public Law
99-158, 42 USC 241 and 285) and administered under PHS grants policies
and Federal Regulations 42 CFR 52 and 45 CFR Part 74.  This program is
not subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.

$$R1 END ************************************************************

$$R2 BEGIN AI-92-11 FULL-TEXT ***************************************

THE EFFECTS OF SILICONE ON THE IMMUNE RESPONSE

NIH GUIDE, Volume 21, Number 30, August 21, 1992

RFA AVAILABLE:  AI-92-11

P.T. 34; K.W. 0710070, 0740070, 0715015

National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases

Letter of Intent Receipt Date:  September 15, 1992
Application Receipt Date:  November 20, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACTS NAMED IN INQUIRIES
BELOW.

PURPOSE

The Division of Allergy, Immunology and Transplantation (DAIT) of the
National Institute of Allergy and Infectious Diseases (NIAID) and the
National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS) invite applications for studies focused on the short- and long-
term effects of silicone polymers and their breakdown products on the
cellular and molecular components of the immune system and its
functions and how these changes might contribute to the initiation of
self-reactivity and the induction of autoimmune disease.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA, The
Effects of Silicone on the Immune Response, is related to the priority
area of diabetes and chronic disabling conditions.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0) or "Healthy People 2000"  (Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC 20402-9325 (telephone
202-782-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by public and private, foreign and
domestic, for-profit and non-profit organizations, public and private,
such as universities, colleges, hospitals, laboratories, units of State
and local governments, and eligible agencies of the Federal Government.
Women and minority investigators are encouraged to apply.  Foreign
institutions are not eligible to apply for the First Independent
Research Support and Transition (FIRST) Award.

MECHANISMS OF SUPPORT

The mechanisms of support for this program will be the research project
grant (R01) and the FIRST Award (R29).  The regulations (CFR Title 42,
Part 52 and, as applicable to State and local governments, Title 45,
Part 74) and policies that govern the research grant programs of the
National Institutes of Health will prevail.  Responsibility for the
planning, direction, and execution of the proposed project will be
solely that of the applicant.  The total project period may not exceed
five years.  The earliest anticipated award date will be July 1, 1993.

This RFA is a one-time solicitation.  Future unsolicited competing
continuation applications will compete with all investigator-initiated
applications and be reviewed according to the customary NIH peer review
procedures.

FUNDS AVAILABLE

Up to $650,000 total costs for the first-year, and additional approved
expenses for up to five years, has been committed to fund applications
submitted in response to this RFA.  The NIAID and the NIAMS plan to
make approximately three and one awards, respectively, in FY 1993,
contingent on the receipt of highly meritorious applications.  Funding
beyond the first and subsequent years of the grant will be contingent
upon satisfactory progress during the preceding years and the
availability of funds.

RESEARCH OBJECTIVES

Silicone-containing implants and silicone injections have been linked
to the development of autoimmune-like diseases, such as scleroderma,
arthritis, and dermatomyositis, in some patients.  However, there are
no solid scientific data to support or rule out the link between the
onset of autoimmune disease and the presence of silicone in intact and
leaky implants.  Furthermore, very limited information is available
regarding the effects of silicone administration on the development of
normal immune responses and the maintenance of self-tolerance.  From
the available preliminary information, it appears that some silicone
polymers (e.g., D4) have biological activity in vivo similar to
Freund's complete adjuvant.  Basic research on the effects of silicone
in the immune system will be valuable in determining the safety of
these devices.

Examples of relevant research topics include, but are not limited to:

o  Effects of short- and long-term administration of silicone on the
production, structure, and function of lymphocytes

o  Effects of intracellular accumulation of silicone and low molecular
weight derivatives in macrophage function, including antigen processing
and presentation, cytokine production, and cytotoxic activities.

o  Characterization of the profiles and fine specificity of
autoantibodies obtained from the sera of patients developing
autoimmune-like syndromes who have also received implants

o  Evaluation of the effects of silicone on lymphocyte and monocyte
interactions with endothelial cells and fibroblasts and the production
and function of adhesion molecules.

o  Analysis of silicone effects on the evolution of autoimmune disease
in experimental systems, with regard to disease induction, course, and
immunologic parameters

STUDY POPULATIONS

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are excluded or inadequately
represented in clinical research, a specific justification must be
provided. Applications without such documentation will not be accepted
for review.

LETTER OF INTENT

Prospective applicants are asked to submit by September 15, 1992, a
letter of intent that includes a descriptive title of the overall
proposed research, the name and institution of the Principal
Investigator, and a list of the names of key investigators and their
institution(s).  The letter of intent is requested in order to provide
an indication of the number and scope of applications to be reviewed to
allow early preparations for review.  The letter of intent is not
binding and does not commit the sender to submit an application, nor is
it a requirement for submission of an application.  The letter of
intent is to be directed to:

Susana A. Serrate-Sztein, M.D.
Chief, Autoimmunity Section
Clinical Immunology Branch
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4A20
Bethesda, MD  20892
Telephone:  (301) 496-7985
FAX:  (301) 402-2571

APPLICATION PROCEDURES

Applications are to be submitted on the research project grant
application form PHS 398 (rev. 9/91).  These application forms are
available in most institutional business offices and may be obtained
from the Office of Grants Inquiries, Division of Research Grants,
National Institutes of Health, 5333 Westbard Avenue, Room 449,
Bethesda, MD 20892, telephone (301) 496-7441.

The application receipt date is November 20, 1992.

REVIEW CONSIDERATIONS

Applications will be reviewed for scientific and technical merit by an
appropriate scientific peer review group convened by the Division of
Research Grants, NIH.  The second level of review will be provided by
the National Advisory Allergy and Infectious Disease Council or the
National Arthritis and Musculoskeletal and Skin Diseases Council in May
1993.

INQUIRIES

It is essential that prospective applicants obtain the full RFA prior
to developing applications.

Direct inquiries regarding this program and requests for the RFA
document to:

Susana A. Serrate-Sztein, M.D.
Chief, Autoimmunity Section
Clinical Immunology Branch
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4A20
Bethesda, MD  20892
Telephone:  (301) 496-7985
FAX:  (301) 402-2571

Dr. Michael D. Lockshin
Director, Extramural Programs
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Building 31, Room 4C31
Bethesda, MD  20892
Telephone:  (301) 496-0802

Direct inquiries regarding fiscal and administrative matters to:

Mr. Jeffrey Carow
Chief, Immunology Grants Management Section
Grants Management Branch
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4B29
Bethesda, MD  20892
Telephone:  (301) 496-7075

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance, No. 93.855 - Allergy, Immunology and Transplantation
Research and No. 93.846 - Arthritis and Musculoskeletal and Skin
Diseases Research.  Grants are awarded under the authority of the
Public Health Service Act, Section 301 (42 USC 241) and administered
under PHS grants policies and Federal Regulations, most specifically at
42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.

$$R2 END ************************************************************

$$R3 BEGIN CA-92-25 FULL-TEXT ***************************************

INTERACTIVE R01S FOR CLINICAL STUDIES OF SYSTEMIC THERAPIES

NIH GUIDE, Volume 21, Number 30, August 21, 1992

RFA AVAILABLE:  CA-92-25

P.T. 34; K.W. 0715035, 0785035, 0745070

National Cancer Institute

Letter of Intent Receipt Date:  October 22, 1992
Application Receipt Date:  December 22, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRES,
BELOW.

PURPOSE

The Cancer Therapy Evaluation Program, Division of Cancer Treatment, at
the National Cancer Institute (NCI) invites Interactive Research
Project Grant (IRPG) applications (R01s) to perform research projects
designed to conduct clinical studies of innovative systemic therapies
investigating promising therapeutic approaches in a single tumor type
or focused on a single class of novel compounds or a mechanism of
action.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Interactive R01s for Clinical Studies of Systemic Therapies, is related
to the priority area of cancer.  Potential applicants may obtain a copy
of "Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0) or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202/783-3238).

ELIGIBILITY REQUIREMENTS

Domestic and foreign, for-profit and non-profit organizations,
governments and their agencies are eligible to apply.  Applications may
be from single institutions or multiple institutions (collaborating
institutions, consortia, cooperative groups).  New and experienced
investigators are encouraged to apply.  Applications from minority
individuals and women are encouraged.  Applicants proposing to perform
phase I clinical trials that address issues on the mechanisms of action
of immunologically active agents are not eligible for this RFA and
should apply for an RFA that will be issued by the Biological Response
Modifiers Program in the near future.

MECHANISM OF SUPPORT

Support of this program will be through the IRPG, an assistance
mechanism composed of three or more investigator-initiated research
grant applications (R01s) that will be reviewed independently for
merit, but that share a theme and resource(s) and require concurrent
funding to maximize the effectiveness of the resource or to allow
maximal creative interaction between researchers.  Except as otherwise
stated in this RFA, awards will be administered under PHS grants policy
as stated in the Public Health Service Grants Policy Statement, DHHS
Publication No. (OASH) 90-50,000, revised October 1, 1990.

This RFA is a one-time solicitation for FY 93.  However, the NCI has
plans to re-issue this RFA for funding in 1994.  If it is determined
that there is a sufficient continuing program need, the NCI will invite
recipients of awards under this RFA to submit competitive continuation
applications for review according to the procedures described below.

FUNDS AVAILABLE

Approximately $4,000,000 in total costs per year for four years will be
committed to fund applications submitted in response to this RFA.  This
funding level is dependent on the receipt of a sufficient number of
applications of high scientific merit.  The total cost for each IRPG
(consisting of three or more R01s) is limited to $750,000 per year.
Thus it is anticipated that five to six IRPGs will be funded in FY 93.
In FY 93, it is anticipated that this RFA will be re-advertised and an
additional three IRPGs will be funded in FY 94.  The total project
period for applications submitted in response to the RFA may not exceed
four years.  The earliest feasible start date for the initial awards
will be August 1993.  Although this program is provided for in the
financial plans of the NCI, the award of R01 grants pursuant to this
RFA is also contingent upon the availability of funds for this purpose.

RESEARCH OBJECTIVES

Background

An unprecedented number of new therapeutic agents are ready for
evaluation in pilot clinical studies.  In addition, insights into the
biologic function and clinical relevance of growth factors, genes that
promote and suppress neoplasia, mechanisms of treatment sensitivity and
resistance, and function of the immune system provide important new
clinical research opportunities for investigators.  The NCI is
interested in expanding support for clinical research.  Under this IRPG
RFA, the NCI encourages the coordinated submission of related research
project grant applications from investigators who want to collaborate
on a common cancer research theme, but do not require extensive shared
physical resources or core functions.  This mechanism is not meant to
replace the program project (P01) mechanism but to support a level of
collaboration between that of the P01 and that available through an
individual R01.

Research Goals And Scope

The aims of this RFA are two-fold:  (1) to provide support for
translational research that brings innovative basic research findings
into the clinic and (2) to foster the development of interactions
between basic science laboratories of different disciplines and
clinicians performing clinical trials to advance therapeutic clinical
research.

This RFA is soliciting applications to perform interactive research
projects with the goal of developing new clinical studies involving
systemic therapies with a therapeutic intent.  The IRPGs may have as
their key focus either:  (1) clinical studies investigating promising
therapeutic approaches in a single tumor type or (2) the development of
new clinical treatment strategies focused on a single class of novel
compounds or mechanism of action.  Each project supported in the IRPG
is expected to contribute to and be directly related to the common
theme of the IRPG application.  The application must clearly explain
how the projected integrated R01 research grants can be expected to
accomplish the stated goal more efficiently and effectively than they
could without the anticipated interactions.  At least one clinical
trial protocol must be proposed in one of the grant applications.  The
clinical trials should be well integrated with the laboratory studies
proposed within the same R01 application or in separate R01
applications.

SPECIAL REQUIREMENTS

The RFA describes the roles and responsibilities of the Principal
Investigator/Awardee and the Project Coordinator.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS FOR INCLUSION OF FEMALES AND MINORITIES IN
CLINICAL RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of females and minorities in
study populations.  If females or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit, by October 22, 1992, a
letter of intent that includes a descriptive title of the proposed
research, the names and addresses of the Principal Investigator, the
names of other investigators and key personnel, the participating
institutions, and the number and title of the RFA in response to which
the application is being submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, it is requested
in order to provide an indication of the number and scope of
applications to be reviewed.

The letter of intent is to be sent to Dr. Roy S. Wu at the address
under INQUIRIES.

APPLICATION PROCEDURES

Applications must be received by December 22, 1992.  If an application
is received after that date, it will be returned to the applicant
without review.  The PHS 398 (rev. 9/91) research grant application
form is to be used in applying for this RFA.  These forms are available
at most institutional business offices; from the Office of Grants
Inquiries, Division of Research Grants, National Institutes of Health,
Room 449, Westwood Building, 5333 Westbard Avenue, Bethesda, MD 20892,
telephone (301) 496-7441; and from the NCI Program Directors named
below.

A short narrative of the interactive nature of the research
applications should be included in the Research Plan of each of the R01
applications.  The exact nature of the interactions should be clearly
detailed under the consortium section of the respective R01
applications.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed by the Division of Research
Grants for completeness.  Incomplete applications will be returned to
the applicant without further consideration.  Evaluation for
responsiveness to the program requirements and criteria stated in the
RFA is an NCI program staff function.  Applications that are judged
non-responsive will be returned to the applicant.  Questions concerning
the responsiveness of proposed research to the RFA are to be directed
to Program Directors (see INQUIRIES).

AWARD CRITERIA

The anticipated date of award is August 1, 1993.  In addition to the
technical merit of the application, the NCI will consider how well the
applicant institution meets the goals and objectives of the program as
described in the RFA, availability of resources, and study populations.

INQUIRIES

Written and telephone inquiries concerning the objectives and scope of
this RFA, inquiries about whether or not specific proposed research
would be responsive, and requests for the RFA are encouraged and are to
be directed to NCI Program Directors at the addresses below.  The NCI
Program Directors welcome the opportunity to clarify any issues or
questions from potential applicants.

For technical information:

Dr. Roy S. Wu
Ms. Diane Bronzert
NCI Program Director
Cancer Therapy Evaluation Program
Division of Cancer Treatment
National Cancer Institute
Executive Plaza North, Room 734
Bethesda, MD  20892
Telephone:  (301) 496-8866
FAX:  (301) 480-4663

For business information:

Ms. Sara Stone
Grants Management Specialist
National Cancer Institute
Executive Plaza South, Room 242
Bethesda, MD  20892
Telephone:  (301) 496-7800, ext. 66
FAX:  (301) 496-8601

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No 93.395, Cancer Treatment Research.  Awards are made under the
authorization of the Public Health Service Act, Title IV Sections 301,
410, and 411, Part A (Public Law 78-410, 42 USC 241 as amended, Public
Law 99-158, 42 USC 285a) and administered under PHS grants policies and
Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74.  This program
is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

$$R3 END ************************************************************

                    ONGOING PROGRAM ANNOUNCEMENTS

$$P1 BEGIN PA-92-101 FULL-TEXT ***************************************

RESEARCH ON ECONOMIC AND SOCIOECONOMIC ASPECTS OF ALCOHOL ABUSE

NIH GUIDE, Volume 21, Number 30, August 21, 1992

PA AVAILABLE:  PA-92-101

P.T. 34; K.W. 0404003, 0408006, 0785055

National Institute on Alcohol Abuse and Alcoholism

THE PROGRAM ANNOUNCEMENT ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL
INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

Alcohol abuse and alcoholism are major problems in the United States,
and costs related to alcohol misuse are a significant economic issue.
The purpose of this Program Announcement (PA) is to make clear the
continued interest of the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) in supporting additional, high-quality research on
economic and socioeconomic aspects of the prevention, treatment, and
epidemiology of alcohol-related problems.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas (DHHS, 1990(a)).
This PA, Research on Economic and Socioeconomic Aspects of Alcohol
Abuse, is related to the priority areas of decreasing morbidity and
mortality that are associated with the drinking of alcohol.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0, or Summary Report: Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign non-profit and
for-profit organizations, whether public or private, such as
universities, colleges, hospitals, laboratories, units of State and
local governments, and eligible agencies of the Federal Government.
Women and minority investigators are encouraged to apply.  Foreign
institutions are not eligible to apply for the First Independent
Research Support and Transition (FIRST) Award.

MECHANISMS OF SUPPORT

Research support may be requested through applications for a regular
research grant (R01), Small Grant (R03), or FIRST Award (R29).
Specialized announcements for the FIRST Award program (R29) and the
Small Grant program (R03) are available from the National Clearinghouse
for Alcohol and Drug Information, P.O. Box 2345, Rockville, MD 20852,
telephone (301) 468-2600 or 1-800-729-6686.

Applicants for R01s may request support for up to five years, Small
Grants are limited to two years, and FIRST Award applicants must
request five years of support.  FIRST and Small Grants are not
renewable, but applications may be submitted for R01 support to
continue research on the same topics.

AVAILABILITY OF FUNDS

No specific set-aside funds are being allocated by the NIAAA for this
program at this time.  Applications received in response to this PA
will compete with others assigned to the NIAAA for funding.  The amount
of funding available will depend on appropriated funds, quality of
research applications and program priorities at the time of the award.
In FY 1992, 29 grants relating to this program area, including new and
continuation grants, were funded for approximately $6 million.

RESEARCH OBJECTIVES

The purpose of this PA is to stimulate research applications in five
areas of study:  (1) the price and availability of alcoholic beverages;
(2) advertising and media portrayals of alcoholic beverages; (3) risk-
taking behavior and its relationship to drinking; (4) the deterrence of
drinking and driving; and (5) the costs and financing of alcoholism
treatment services.

Background

Economic considerations often have a strong direct or indirect effect
on the levels of alcohol consumption and on the levels of
alcohol-related problems.  The price and availability of alcoholic
beverages, for example, have been shown to affect alcohol consumption,
morbidity, and mortality.  Advertising by the alcohol industry supports
a significant share of prime-time television, but the effects of
advertising on alcohol use and abuse are still not clear.  Public
information campaigns, alone or in combination with more personalized
approaches, may be used to prevent alcohol problems, but the
cost-effectiveness of such intervention strategies should be more
firmly established.  Risk-taking behavior may be conceptualized in
economic terms according to rational and quasi-rational models of
decision-making.  Costs, as well as other social policy considerations,
affect the choice of strategies for deterring drinking and driving and
the ways such interventions are implemented.  The costs and methods of
financing alcoholism treatment are also of interest in the PA.

Scope

Some examples of research topics that would be considered responsive to
this announcement include the following:

o  the effects of price changes and availability controls on levels of
alcohol consumption and alcohol-related problems

o  variations in price and income elasticities among different types of
drinkers (heavy, moderate, light) or among demographic subgroups (e.g.
youth)

o  the impact of changes in alcohol taxation on economic efficiency,
equity, and the public health

o  the impact of advertising on the development of alcohol expectancies
and drinking behavior, especially among youth

o  the effectiveness of health promotion messages

o  the development and testing of cost-benefit models of risk taking
behavior, especially among youth

o  the effects of types, levels, and combinations of sanctions in
producing both general and specific deterrence to drinking and driving

o  evaluations of non-sanction-based deterrence initiatives for
drinking driving such as server intervention, designated driver
campaigns, and the provision of alternative means of transportation

o  the costs and cost offsets of different modalities for the treatment
of alcoholism

o  the relationships between treatment factors, patient
characteristics, facility characteristics, and treatment costs

o  patterns of treatment utilization and treatment seeking
characteristics

STUDY POPULATIONS

SPECIAL INSTRUCTIONS ON THE INCLUSION OF MINORITIES AND WOMEN AS
SUBJECTS IN RESEARCH

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

APPLICATION PROCEDURES

Applicants are to use the grant application form PHS 398 (rev. 9/91).
The number and title of this program announcement, PA-92-101, Research
on Economic and Socioeconomic Aspects of Alcohol Abuse, must be typed
in item number 2a on the face page of the PHS 398 application form.

Application kits containing the necessary forms and instructions may be
obtained from business offices or offices of sponsored research at most
universities, colleges, medical schools, and other major research
facilities.  If such a source is not available, the following office
may be contacted for the necessary application material:

National Clearinghouse for Alcohol and Drug Information
P.O. Box 2345
Rockville, MD  20852
Telephone:  (301) 468-2600

The signed original and five permanent, legible copies of the completed
application must be submitted to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

REVIEW CONSIDERATIONS

The Division of Research Grants, NIH, serves as the central point for
receipt of applications for most discretionary PHS grant programs.
Applications received under this announcement will be assigned to
Initial Review Groups (IRGs) in accordance with established PHS
Referral Guidelines.  The IRG, consisting primarily of non-Federal
scientific and technical experts, will review the applications for
scientific and technical merit.  Notification of the review
recommendations will be sent to the applicant after the initial review.
Applications will receive a second-level review by an appropriate
National Advisory Council, whose review may be based on policy
considerations as well as scientific merit.  Only applications
recommended by the Council may be considered for funding.

AWARD CRITERIA

Applications recommended by a National Advisory Council will be
considered for funding on the basis of overall scientific and technical
merit of the research as determined by peer review, program needs and
balance, and availability of funds.

INQUIRIES

Potential applicants are encouraged to seek preapplication
consultation.  They may contact any of the following for information on
preparing an application.

Michael Hilton, Ph.D.
Prevention Research Branch
Division of Clinical and Prevention Research
National Institute on Alcohol Abuse and Alcoholism
5600 Fishers Lane, Room 13C-23
Rockville, MD  20857
Telephone:  (301) 443-1677

Inquiries relating to fiscal matters are to be directed to:

Elsie Fleming
Grants Management Branch
Office of Planning and Resource Management
National Institute on Alcohol Abuse and Alcoholism
5600 Fishers Lane, Room 16-86
Rockville, MD  20857
Telephone:  (301) 443-4703

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance, No. 93.273.  Awards are made under the authority of
Sections 301 and 510 of the Public Health Service Act, as amended (42
USC 241 and 290bb).  Federal regulations at 42 CFR Part 52, "Grants for
Research Projects," and Title 45 CFR Parts 74 and 92, generic
requirements concerning the administration of grants, are applicable to
these awards.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.

$$P1 END ************************************************************

$$P2 BEGIN PA-92-102 *************************************************

RESEARCH ON SURVEILLANCE AND RELATED STUDIES OF SPORTS INJURY IN YOUTH

NIH GUIDE, Volume 21, Number 30, August 21, 1992

PA NUMBER:  PA-92-102

P.T. 34; K.W. 0785205, 0715027, 0745030

National Institute of Arthritis and Musculoskeletal and Skin Diseases

PURPOSE

The National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS) invites grant applications to conduct surveillance and
related research projects on sports injury in youth.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This Program
Announcement, Research on Surveillance and Related Studies of Sports
Injury in Youth, is related to the priority area of physical activity,
fitness, and unintentional injuries.  Potential applicants may obtain
a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0) or "Healthy People 2000" (Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign, non-profit and
for-profit, public and private organizations, such as universities,
colleges, hospitals, laboratories, units of State and Local
governments, and eligible agencies of the Federal Government.  However,
foreign institutions are not eligible for the First Independent
Research Support and Transition (FIRST) Award (R29) and the career
development awards (K04, K08, K11).  Applications from minority
individuals and women are encouraged.

MECHANISMS OF SUPPORT

Support will be offered through research project grants (R01), FIRST
Awards (R29), research fellowship training awards (F32, F33), and
research career development awards (K04, K08, K11).

RESEARCH OBJECTIVES

Sports and exercise activity in youth are critical to developing and
maintaining physical fitness and general well-being.  These fitness
patterns established in youth may provide the basis for a healthy
life-style throughout adult life.  The occurrence of injuries has been
accepted as a natural risk associated with exercise and especially with
sports participation.  Of the estimated 8 million youth participating
in sports at the junior high and high school level, approximately 25
percent incurred some form of injury.  Therefore, the physical and
financial impact is significant.

One means of reducing these injuries is to understand the nature and
risk factors for sports injuries and to seek preventive measures to
reduce the occurrence.  Injury surveillance approaches have led to
important changes in rules and equipment to reduce the rate of injury.
In one case, trampolines, the nature of the sport could not be modified
to improve safety, therefore, the sport has been eliminated.

On April 8-9, 1991, at the Lister Hill Center of the NIH a conference
was held on Sports Injuries in Youth:  Surveillance Strategies.  This
meeting was co-sponsored by the National Advisory Board for Arthritis
and Musculoskeletal and Skin Diseases, NIAMS, and the Centers for
Disease Control.  The purpose of the Conference was to examine the
various factors required to develop and operate a surveillance system.
Successful systems and problem areas were described.  The resulting
information will provide guidance for researchers entering areas of
investigation involving development and utilization of reliable data
bases in the field of scholastic sports injury.  Published proceedings
from the conference are available from the contact person listed below
under INQUIRIES.

The epidemiologic definition of surveillance is the dynamic, close, and
continued watchfulness over the distribution and trends of disease
occurrence through systematic collection, tabulation, and analysis of
relevant mortality and morbidity data.  Essential steps in this process
include data collection, entry, processing, analysis, interpretation,
and presentation.  A weakness in any of these procedures may result in
incomplete, inaccurate, improper, or poorly disseminated findings.  One
of the critical elements in analyzing sports surveillance data is the
determination of the rate (incidence/number of persons at risk) of
injury.  For example, all players on a basketball team may not be at
equal risk, since some may not even enter the game.  Issues such as
these are well defined in the conference proceedings.

The suggested areas for future research that were developed during the
conference were defined in the proceedings as:

o  Developing surveillance systems for consistent national data
collection;
o  Developing a national sports injury data base;
o  Injury characterization and intervention schemes;
o  Coordination of data from diverse sources;
o  Developing methods for "small area sampling" of special injury
situations;
o  Evaluating re-injury rates and risks;
o  Expanding surveillance to include intramural and extra-scholastic
sports;
o  Expanding injury surveillance to include primary grades;
o  Comparing injury rates and conditions to college and professional
sports;
o  Considering a wide range of external factors that may add to risks;
and
o  Developing and evaluating instructional prevention programs.

These areas of research are neither prioritized nor meant to be
restrictive.  Investigators are encouraged to submit applications in
any meritorious area of research responsive to the general research
objectives of this Program Announcement.  In addition to projects that
specifically address surveillance methodology to uncover risks of and
the nature of injuries, the NIAMS will consider to be responsive to
this announcement applications that include biomechanical, biochemical,
or other approaches to elucidating the mechanism of injury.  Such
related studies should either (1) be a component of applications for
surveillance-based research or (2) be based on the findings of other
surveillance data indicating that a particular mechanism may be the
cause of injury.

The project should be founded on a strong hypothesis as evidenced by
preliminary data of the investigator or others.  All data collection
and statistical procedures should be fully defined and justified.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements are required to include
minorities and women in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder or
condition under study.  Special emphasis must be placed on the need for
inclusion of minorities and women in studies of diseases, disorders and
conditions which disproportionately affect them.  This policy is
intended to apply to males and females of all ages.  If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale must be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of the
study.  This information must be included in Form PHS 398 in Sections
1-4 of the Research Plan and then summarized in Section 5, Human
Subjects.  Applicants are urged to assess carefully the feasibility of
including the broadest possible representation of minority groups.
However, NIH recognizes that it may not be feasible or appropriate in
all research projects to include representation of the full array of
United States racial/ethnic minority populations (i.e., Native
Americans (including American Indians or Alaskan Natives),
Asian/Pacific Islanders, Blacks, and Hispanics).  The rationale for
studies on single minority population groups must be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including, but not limited to, clinical
trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.  If the required information is not contained within the
application, the review will be deferred until the information is
provided.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed and the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in the
priority score assigned to the application.

All applications for clinical research submitted to NIH are required to
address these policies.  NIH funding components will not award grants
or cooperative agreements that do not comply with these policies.

APPLICATION PROCEDURES

Applications are to be submitted on grant application form PHS 398
(rev. 9/91), except for individual fellowship applications which must
be submitted on form PHS 416-1 (rev. 10/91).  Applications will be
accepted at the standard application deadlines indicated in the
application kits.

Application kits are available at most institutional business offices
and may also be obtained from the Office of Grants Inquiries, Division
of Research Grants, National Institutes of Health, Westwood Building,
Room 449, Bethesda, MD 20892, telephone 301/496-7441.  The title and
number of the announcement must be typed in Section 2a on the face page
of form PHS 398.

The completed original application and five legible copies of form PHS
398 or two copies of form PHS 416-1 must be sent or delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

REVIEW CONSIDERATIONS

Applications will be assigned on the basis of established Public Health
Service referral guidelines.  Applications will be reviewed for
scientific and technical merit by initial review groups of the Division
of Research Grants, NIH, or by the review group of the appropriate
Institute, Center, or Division (ICD), in accordance with the standard
NIH peer review procedures.  Following scientific-technical review,
applications will receive a second-level review by the appropriate
national advisory council.

AWARD CRITERIA

Applications will compete for available funds with all other approved
applications assigned to that ICD.  The following criteria will be
considered in the making of funding decisions:

o  Quality of the proposed project as determined by peer review;
o  Availability of funds; and
o  Program balance among research areas of the announcement.

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Stephen L. Gordon, Ph.D.
Chief, Musculoskeletal Diseases Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 407
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 402-3338

Direct inquiries regarding fiscal matters to:

Ms. G. Carol Clearfield
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 726B
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 402-3360

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.846, (Arthritis, Musculoskeletal and Skin Disease Research).
Awards will be made under the authority of the Public Health Service
Act, Title III, Section 301 (Public Law 410, 78th Congress, as amended,
42 USC 241) and administered under PHS grants policies and Federal
Regulations 42 CFR 52 and 45 CFR Part 74.  This program is not subject
to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency review.

$$P2 END ************************************************************

                               ERRATA

$$E1 BEGIN N1 19920710 APPEND NOTICE ***********************************

RESEARCH SUPPLEMENTS TO PROMOTE REENTRY INTO BIOMEDICAL AND BEHAVIORAL
RESEARCH CAREERS

NIH GUIDE, Volume 21, Number 30, August 21, 1992

P.T. 34, II; K.W. 0710030, 1014006

National Institutes of Health

This announcement that appeared in the NIH Guide for Grants and
Contracts, Vol. 21, No. 25, July 10, 1992, contained an incorrect
address for the National Institute of Allergy and Infectious Diseases.
The following is the correct address:

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES:

Milton J. Hernandez, Ph.D.
Director, OSTMD, DEA, NIAID
Solar Building,  Room 4C10
Bethesda, MD  20892
Telephone:  (301) 496-7291

APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE
ADDRESS FOR THE SOLAR BUILDING IS:

6003 Executive Boulevard
Rockville, MD  20852

$$E1 END ************************************************************